Latest From Sten Stovall
Small- to medium-sized drug makers developing new products for resistant infections are increasingly partnering with players in emerging markets such as China because of the absence of workable risk/reward systems in rich countries, according to a report by The Access To Medicine Foundation.
SNIPR BIOME aims to be the world’s top developer of CRISPR-based drugs that selectively target and kill bacteria, while leaving the rest of the patient’s microbiome intact, the biotech’s CEO tells Scrip.
French biotech GenSight will prioritize its optogenetic GS030 treatment after the combination showed breakthrough results in a form of blindness, its CEO tells Scrip.
Novo Nordisk has initiated its Phase III trial assessing its oral GLP-1 semaglutide in early Alzheimer’s disease patients. The firm’s veteran GLP-1 agonist pioneer Lotte Bjerre Knudsen explains its promise to Scrip.
Post-Brexit Britain offers a fertile R&D ecosystem, but it needs to improve uptake in novel medicines there and strike a lasting deal with the EU over batch testing, Novo Nordisk’s UK general manager Pinder Sahota tells Scrip.
Emerging Company Profile: Denmark-based start-up ADCendo says it now has enough money to begin developing antibody-drug conjugates aimed at the novel cancer target uPARAP/Endo180 and deliver proof of concept in humans for one or more indications by the end of 2025.